FDA approves anti-bleeding drug from CSL

01/19/2009 | Reuters

The FDA granted clearance for CSL's Riastap, an intravenous drug derived from human plasma that treats a bleeding disorder called congenital fibrinogen deficiency. The approval was based on results from a clinical study that reported improved clot firmness in 14 out of 15 participants, the agency said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA